Hepatitis Drugs Market Size, Share, Growth and Forecast, 2025-2035

Lifelong hepatitis B care and cure-focused agents lead value

The global hepatitis drugs market was valued at USD 24.43 billion in 2025 and is projected to increase from USD 25.90 billion in 2026 to USD 43.88 billion by 2035, registering a CAGR of 6.03% during 2026–2035. Demand comes from the 254 million people living with chronic hepatitis B, most of whom need daily antiviral tablets for years, and from 50 million people with hepatitis C who can be cured with short oral courses. North America held the largest regional share, 41.0% in 2025, on high branded prices and broad insurance coverage for curative regimens. Asia Pacific is the fastest-growing region at 7.23% a year, as China, India and other high-burden countries expand testing and treatment. The main change is the arrival of functional cure candidates for hepatitis B, led by an antisense medicine under FDA priority review, while generic direct-acting antivirals keep pushing hepatitis C prices lower.

Which antiviral treatments count toward total value?

The market counts manufacturer revenue from prescription medicines used to treat chronic and acute viral hepatitis. It covers nucleoside and nucleotide analogues such as tenofovir and entecavir, direct-acting antiviral regimens for hepatitis C, peginterferon and newer immune modulators and antiviral agents for hepatitis B and hepatitis D. Buyers include hospital, retail and online pharmacies, public health programs and private insurers.

The scope excludes vaccines, diagnostic tests, liver transplant services and medicines used only to manage complications such as ascites or liver cancer. Value flows from originators and generic makers through wholesalers and pharmacies to patients, with public tenders setting prices in many low- and middle-income countries.

Hepatitis B and nucleoside analogues hold most value

Why does hepatitis B hold the largest share?

Based on disease type, the market is categorized into hepatitis B, hepatitis C and other hepatitis. Hepatitis B led with 52.0% of 2025 value, because chronic infection usually requires daily suppressive therapy for many years. Other Hepatitis grows fastest at 8.40% a year, as treatments for hepatitis D move through late-stage trials. Hepatitis C value grows more slowly, because short curative courses and generic regimens reduce spending per patient.

How do antiviral classes divide value?

Based on drug class, the market is categorized into direct-acting antivirals, interferons, nucleoside and nucleotide analogues, and immune modulators. Nucleoside and Nucleotide Analogues led with 44.0% of 2025 value, because tenofovir and entecavir remain first-line hepatitis B therapy. Immune Modulators grow fastest at 10.13% a year, as functional cure candidates such as bepirovirsen, counted in this group, approach approval. Interferons continue to lose share as doctors move patients to oral treatment.

Where do patients fill antiviral prescriptions?

Based on distribution channel, the market is categorized into hospital pharmacy, retail pharmacy, online pharmacy and others. Retail Pharmacy led with 45.0% of 2025 value, because patients refill long-term hepatitis B tablets at community pharmacies. Online Pharmacy grows fastest at 7.94% a year, as insurers and patients use mail-order and digital pharmacies for specialty courses and monthly refills.

Wider testing, new guidelines and functional cure trials

How does a large undiagnosed population sustain demand?

Viral hepatitis remains a leading infectious cause of death, and most infected people have not yet been diagnosed. WHO data released in April 2024 show that viral hepatitis deaths rose to 1.3 million in 2022, with hepatitis B causing 83% of them. Only 13% of people with hepatitis B and 36% of people with hepatitis C had been diagnosed by the end of 2022, and just 20% of people with hepatitis C had been cured. As a result, every new testing campaign moves patients into long-term treatment or curative therapy.

Why do new WHO guidelines widen treatment eligibility?

Treatment rules for hepatitis B have long been complex, which kept many eligible patients off therapy. On March 29, 2024, WHO published updated hepatitis B guidelines with simplified treatment criteria for adults and adolescents and wider antiviral prophylaxis for pregnant women. These changes let primary care workers start therapy without specialist tests in many settings. In turn, more patients in high-burden countries become eligible for daily tenofovir or entecavir, which lifts generic volume in the hepatitis drugs market through the decade.

Download Free Sample

How do functional cure trials attract investment?

Current hepatitis B tablets suppress the virus but rarely clear it, so patients often take them for life. In May 2026, pooled phase 3 B-Well data showed that 19% of patients on bepirovirsen reached functional cure versus 0% on standard care alone. In April 2026, GSK and Ionis announced FDA priority review with an action date of Oct. 26, 2026, and the medicine is also under review in the EU, China and Japan. A finite cure would add a premium branded class to the market.

Why does acute hepatitis C treatment add patients?

Doctors once waited months to see whether acute hepatitis C infections cleared without treatment, which delayed care. In June 2025, the FDA approved an expanded indication for AbbVie's Mavyret in acute hepatitis C, making it the first treatment for this stage with an 8-week course. The approval allows immediate treatment after diagnosis, which helps stop onward transmission among people who inject drugs. This change adds new patients to the direct-acting antiviral pool and supports demand for hepatitis drugs in U.S. outreach programs.

Functional cure, delta virus agents and acute HCV care

Why is functional cure research gaining ground?

Research is shifting from lifelong viral suppression toward finite treatment that clears hepatitis B surface antigen. Bepirovirsen, an antisense medicine, met its primary endpoint in two phase 3 trials that enrolled over 1,800 patients across 29 countries. Response was higher in patients with low baseline antigen levels, where 26% reached functional cure. This shift points to a new branded segment that could raise spending per treated patient after 2026.

How are hepatitis D treatments emerging?

Hepatitis D is the most severe form of chronic viral hepatitis, yet the U.S. still has no approved treatment for it. In August 2025, Vir Biotechnology initiated all trials in its ECLIPSE registrational program for tobevibart plus elebsiran, including a head-to-head study against bulevirtide. The combination holds FDA Breakthrough Therapy and EMA PRIME status. As a result, other hepatitis becomes the fastest-growing disease group through 2035.

Download Free Sample

Where is the opening in high-burden countries?

High-burden countries offer a large opening for low-cost generic suppliers, because ten countries carry nearly two-thirds of the global hepatitis B and C burden. WHO sets a benchmark price of USD 2.4 a month for generic tenofovir and USD 60 for a 12-week sofosbuvir and daclatasvir course. Indian makers such as Dr. Reddy's, Zydus and Aprazer supply these regimens at scale. Public programs in India, Pakistan and Egypt can therefore treat far more patients within fixed budgets.

Can wider testing and digital pharmacy add volume?

Simpler testing creates an opening to find more patients outside hospitals and specialist clinics. In July 2024, WHO announced it had prequalified the first hepatitis C self-test, which lets people test at home before seeking confirmatory care. Linked services such as HIV testing programs already reach many of the same high-risk groups. Patients diagnosed through these routes can then receive treatment through e-pharmacy services that deliver medicine to the home.

Low diagnosis, price erosion and stigma limit uptake

How does low diagnosis limit treated volume?

Most people with chronic hepatitis feel well for years, so they rarely seek testing until the liver is damaged. WHO data show that only about 3% of people with hepatitis B received antiviral therapy by the end of 2022. Without diagnosis, millions of eligible patients never fill a prescription, which holds market volume well below the size of the infected population. Integrating testing into primary care and antenatal services is the main way to close this gap.

Why does generic price erosion reduce value?

Generic tenofovir and direct-acting antivirals have pushed prices down sharply in most low- and middle-income countries. Only 7 of 26 reporting countries paid at or below the WHO benchmark for tenofovir, and only 4 of 24 did so for a hepatitis C course. As tenders push more countries toward these benchmarks, spending per patient keeps falling. This erosion holds hepatitis C value growth well below patient growth in many markets.

What keeps hepatitis C value from rising?

Hepatitis C is curable in most patients within 8 to 12 weeks, so every successful course removes a patient from the treatment pool. WHO reports that 12.5 million people had been cured by the end of 2022, which leaves a smaller and harder to reach group. Remaining patients often include people who inject drugs and people in prison, who need outreach services. Because of these limits, hepatitis C sales depend on new screening programs.

Why do safety and access gaps slow uptake?

Long-term antiviral therapy needs regular monitoring, and stopping hepatitis B tablets can cause severe flares of liver disease. Clinics must track liver tests and viral load, which strains services in rural areas. Only about one third of African Region countries offer free public testing and treatment, according to WHO. These gaps keep many patients untreated even where low-cost generic medicines are available.

North America leads while Asia Pacific grows fastest

North America leads on branded antiviral prices

North America held a 41.0% share of 2025 value and grows at 5.43% a year through 2035. The U.S. leads spending, because branded hepatitis C regimens and hepatitis B tablets carry higher prices than in other regions. Insurers and Medicaid programs cover curative treatment, and the acute hepatitis C approval in 2025 adds new patients. A possible bepirovirsen approval in late 2026 could add a premium hepatitis B option, while liver cancer screening brings more chronic patients into specialist care.

Asia Pacific grows on testing and treatment programs

Asia Pacific held a 27.0% share of 2025 value and is the fastest-growing region at 7.23% a year. China, India, Indonesia, the Philippines and Vietnam are among the ten countries that carry nearly two-thirds of the global burden. Wider screening and simpler WHO treatment rules bring more hepatitis B patients onto daily therapy. Japan and South Korea add value through branded medicines and early access to new agents.

Download Free Sample

Europe balances new agents and tight budgets

Europe held a 22.0% share of 2025 value and grows at 5.23% a year, the slowest pace among the five regions. Germany, France, Italy, Spain and the U.K. account for most demand, and bulevirtide is already used for hepatitis D in parts of the region. Bepirovirsen is under EMA review, which could add a new option. However, health technology assessment and generic substitution keep prices below U.S. levels.

Latin America relies on public programs

Latin America held a 5.0% share of 2025 value and grows at 6.53% a year through 2035. Brazil and Mexico lead demand through national programs that buy generic tenofovir and hepatitis C regimens in large tenders. Budget limits slow access to newer branded agents across the region.

Middle East and Africa start from a low base

The Middle East & Africa held a 5.0% share of 2025 value and grows at 6.93% a year. The African Region accounts for 63% of new hepatitis B infections, yet treatment coverage remains low. Egypt and Gulf states lead regional spending through national testing and treatment programs.

Download Free Sample

Guidelines, approvals and trial results since 2024

Antisense, antibodies and pangenotypic regimens advance

• Antisense oligonucleotides such as bepirovirsen lower viral proteins and can lead to functional cure of hepatitis B in some patients.
• Monoclonal antibodies with siRNA such as tobevibart plus elebsiran target hepatitis D through two mechanisms in one regimen.
• Pangenotypic direct-acting antivirals such as glecaprevir with pibrentasvir cure hepatitis C across genotypes in eight weeks.
• Entry inhibitors such as bulevirtide block the virus from entering liver cells in patients with hepatitis D.
• Prodrug nucleotide analogues such as tenofovir alafenamide suppress hepatitis B with lower doses and less effect on kidneys and bone.

Originators defend brands as generic makers widen access

Competition splits into originators of branded antivirals, developers of functional cure agents and generic makers. Gilead Sciences holds a broad hepatitis B and C portfolio that includes tenofovir alafenamide and sofosbuvir-based regimens, and AbbVie competes in hepatitis C with Mavyret. Bristol-Myers Squibb, Merck, Roche and Novartis hold older antiviral and interferon brands that now face generic competition. GlaxoSmithKline is moving into hepatitis B with bepirovirsen, and Johnson & Johnson rounds out the group of large diversified companies tracked in this report. Dr. Reddy's Laboratories, Zydus Cadila and Aprazer Healthcare supply low-cost generic tenofovir, entecavir and direct-acting antivirals to public programs in Asia, Africa and Latin America. Companies compete on cure rates, safety, pediatric labels and price, with public tenders deciding most hepatitis drugs volume. In March 2024, Gilead also announced FDA approval of Vemlidy for children aged 6 and older weighing at least 25 kg.

Companies profiled and their roles in this market

Functional cure agents open a new branded cycle

Credence Research's view is that functional cure agents for hepatitis B will open a new branded cycle that offsets continued price erosion in hepatitis C. The 19% functional cure rate for bepirovirsen is modest, but it gives doctors a finite option for patients with low antigen levels. Hepatitis D treatments add a smaller patient group with high value per patient. At the same time, generic makers gain volume as WHO guidelines widen eligibility in high-burden countries, so both branded and generic suppliers can grow on different measures.

How the 2025 baseline and forecast were built

The report uses 2025 as the base year and forecasts market value to 2035, with growth rates stated for 2026–2035. Market values come from the Credence Research market model, which combines treated patient numbers, typical regimen length and average selling prices by region and channel. Splits by disease type, drug class, distribution channel and region are Credence Research estimates. Sources used include WHO data and guidelines, FDA decisions and company press releases. No primary interviews or surveys were used to build the estimates in this report.

Cure-focused therapy and wider access shape 2035

By 2035, the market reaches USD 43.88 billion, with value moving toward functional cure agents for hepatitis B and new treatments for hepatitis D. Hepatitis B remains the largest disease group as more patients are diagnosed and treated. Hepatitis C value stays under pressure from generic regimens and a shrinking untreated pool. Asia Pacific gains share as screening widens in China and India. Progress toward the WHO goal of treating 80% of people with chronic infection will decide how quickly volume grows.

Note: The depth of individual sections depends on data availability for this market. Volume, capacity, trade and other unit-based metrics are included where applicable.